Medytox announced on August 4 that it held the 'MAP Symposium,' an academic event for medical professionals, at the Grand Mercure Ambassador Imperial Palace Seoul Gangnam.


Medical professionals participating in the academic event 'MAP Symposium' hosted by Medytox on the 2nd are taking a commemorative photo. Medytox

Medical professionals participating in the academic event 'MAP Symposium' hosted by Medytox on the 2nd are taking a commemorative photo. Medytox

View original image

This symposium was the first event following the launch of the new academic education program 'MAP.' Experts with clinical experience using major Medytox products served as speakers to share the latest treatment trends and clinical strategies. More than 180 medical professionals from across the nation—including Seoul, Gyeonggi, Incheon, Busan, Cheonan, and other regions—attended the event.


Nam Gijin, Director of Doctor Evers Clinic Gangnam, presented on the topic ‘Coretox: A New Standard for Botulinum Toxin Treatment with Resistance in Mind,’ discussing the mechanisms of resistance expression, prevention guidelines, and the clinical data of the botulinum toxin product 'Coretox.'


Woo Sihyung, Director of Doctor Evers Clinic Cheonan, gave a lecture titled ‘Why Choose COL-SAN (CA): The Clinical Value of Fat Reduction Injectable Newbejou,’ sharing firsthand experience and know-how gained from administering Newbejou. Lee Seokhan, Director at Ilsan, introduced the product features of the hyaluronic acid (HA) filler 'Neuramis' and explained strategies for lip filler procedures based on anatomical understanding.


Lee Sangyun, CEO of Neumeco, a Medytox affiliate, who attended the event, said, "We will actively support the operation of the newly launched academic program 'MAP' to ensure that Medytox’s diverse products and procedural expertise can be effectively utilized in clinical practice."



A Medytox representative stated, "At this symposium, a wide range of academic discussions took place covering major Medytox products—from botulinum toxin formulations to fat reduction injectables and hyaluronic acid fillers. Going forward, we will continue to support hospitals and clinics in enhancing their treatment and procedural capabilities, contributing to the advancement of Korea’s medical aesthetics industry."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing